BioNano Genomics BNGO 深 滬
等待開盤 09-24 09:30:00 美东时间
1.70
-0.120
-6.59%
華盛通- 最 高1.8299
- 今 開1.81
- 成交量 91.31万股
- 最 低 1.6818
- 昨 收 1.82
- 總市值 2.00万
- 52周最高 2.23
- 市盈率 靜 --
- 換手率 7752.98%
- 52周最低 1.00
- 委 比 70.54%
- 總股本 1.18万
- 歷史最高 9414.00
- 量 比 0.61
- 振 幅 8.14%
- 歷史最低 1.00
- 每 手 1
- 風險率 0.27%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BioNano Genomics Highlights Optical Genome Mapping Strategy
BioNano Genomics ( ($BNGO) ) has issued an announcement. On September 14, 2026,...
09-14 21:01
Bionano Genomics Subsidiary Says MolDX Issues Proposed LCD For Genome-Wide Molecular Methodologies For Detection Of Copy Number Alterations And Structural Variants In Hematologic Neoplasms
Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (NASDAQ:BNGO) that offers CLIA-certified laboratory developed test (LDTs), today announced that MolDX, a program that assesses molecular diagnostic technologies on behalf of Medicare Administrative Contractors (MACs), has issu...
09-10 21:02
Bionano Genomics Names Alex Hastie Chief Scientific Officer
BioNano Genomics ( ($BNGO) ) just unveiled an announcement. On June 24, 2026, B...
06-24 21:01
BioNano Genomics Announces Resignation of Chief Medical Officer
BioNano Genomics ( ($BNGO) ) has shared an announcement. On June 2, 2026, Biona...
06-06 05:21
Transcript: Bionano Genomics Q1 2026 Earnings Conference Call
Bionano Genomics (NASDAQ:BNGO) reported first-quarter financial results on Wedn...
05-14 05:10
Bionano Genomics Q1 EPS $(0.76) Beats $(0.95) Estimate, Sales $6.687M Beat $6.567M Estimate
Bionano Genomics (NASDAQ:BNGO) reported quarterly losses of $(0.76) per share which beat the analyst consensus estimate of $(0.95) by 20 percent. This is a 33.91 percent increase over losses of $(1.15) per share from the
05-14 04:11
Bionano Genomics Sees Q2 Sales $7.500M-$7.800M vs $7.520M Est
Bionano Genomics (NASDAQ:BNGO) sees Q2 sales of $7.500 million-$7.800 million vs $7.520 million analyst estimate.
05-14 04:08
Bionano Genomics Affirms FY2026 Sales Guidance of $30.000M-$33.000M vs $32.137M Est
Bionano Genomics (NASDAQ:BNGO) affirms FY2026 sales outlook from $30.000 million-$33.000 million to $30.000 million-$33.000 million vs $32.137 million estimate.
05-14 04:07
Earnings Scheduled For May 13, 2026
Companies Reporting Before The Bell • Similarweb (NYSE:SMWB) is estimated to re...
05-13 19:11
Bionano Genomics Appoints Chairman Al Luderer Interim President, CEO, Effective Immediately
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Al Luderer, Ph.D., chairman of Bionano's Board of Directors, has been appointed interim president and chief executive officer, effective May 5, 2026. Dr. Luderer
05-07 04:49
